SanBio Company Income Statement

Financials in millions JPY. Fiscal year is February - January.

Millions JPY. Fiscal year is Feb - Jan.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jan '26 Jan 31, 2026	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022
Selling, General & Admin	1,116	1,159	1,690	1,781	1,665
Research & Development	2,678	2,357	2,849	6,118	4,955
Operating Expenses	3,794	3,516	4,539	7,899	6,620
Operating Income	-3,794	-3,516	-4,539	-7,899	-6,620
Interest Expense	-36	-8	-10	-26	-44
Interest & Investment Income	6	2	2	4	5
Currency Exchange Gain (Loss)	-326	622	1,746	3,326	1,961
Other Non Operating Income (Expenses)	-141	-120	-23	-103	119
EBT Excluding Unusual Items	-4,291	-3,020	-2,824	-4,698	-4,579
Gain (Loss) on Sale of Assets	-	2	33	1	-
Asset Writedown	-	-	-3	-	-10
Other Unusual Items	-	9	252	-	29
Pretax Income	-4,291	-3,009	-2,542	-4,697	-4,560
Income Tax Expense	-449	-127	102	862	117
Net Income	-3,842	-2,882	-2,644	-5,559	-4,677
Net Income to Common	-3,842	-2,882	-2,644	-5,559	-4,677
Shares Outstanding (Basic)	73	69	65	58	52
Shares Outstanding (Diluted)	73	69	65	58	52
Shares Change (YoY)	6.17%	5.42%	12.78%	11.83%	0.01%
EPS (Basic)	-52.55	-41.85	-40.48	-95.98	-90.31
EPS (Diluted)	-52.55	-41.85	-40.48	-95.98	-90.31
Free Cash Flow	-3,792	-3,607	-4,776	-7,441	-6,588
Free Cash Flow Per Share	-51.86	-52.38	-73.11	-128.47	-127.21
EBITDA	-3,786	-3,507	-4,525	-7,875	-6,488
D&A For EBITDA	8	9	14	24	132
EBIT	-3,794	-3,516	-4,539	-7,899	-6,620

Updated Jan 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.